10-Q: Arrowhead Pharmaceuticals Soars on Sarepta Milestones, Plozasiran NDA Progress

Arrowhead Pharmaceuticals reported a significant financial turnaround and pipeline advancements, driven by its Sarepta collaboration and key regulatory progress for plozasiran.

Summary

• Reported net income of $22.1 million for the nine months ended June 30, 2025, a substantial improvement from a net loss of $429.0 million in the prior year period.
• Revenue for the nine months ended June 30, 2025, surged to $573.0 million, primarily due to the Sarepta Collaboration Agreement.
• Cash, cash equivalents, and restricted cash increased to $129.8 million, with available-for-sale securities reaching $770.6 million as of June 30, 2025.
• Triggered a $100.0 million milestone payment from Sarepta Therapeutics on July 27, 2025, for ARO-DM1, with potential for an additional $200.0 million in near-term milestones.
• Sanofi will acquire rights to plozasiran in Greater China from Visirna, a majority-owned subsidiary, for an upfront payment of $130.0 million and up to $265.0 million in future milestones.
• The FDA accepted the New Drug Application (NDA) for plozasiran (FCS) on January 17, 2025, setting a Prescription Drug User Fee Act (PDUFA) action date of November 18, 2025, and indicated no advisory committee meeting is currently planned.
• Completed enrollment for three Phase 3 clinical trials (SHASTA-3, SHASTA-4, and MUIR-3) of plozasiran for severe hypertriglyceridemia.
• Initiated the YOSEMITE Phase 3 clinical trial for zodasiran, a potential treatment for homozygous familial hypercholesterolemia (HoFH).
• Initiated Phase 1/2a clinical trials for ARO-ALK7 (obesity) and ARO-INHBE.
• Topline results from a Phase 1/2 clinical study of ARO-C3 showed reductions in alternative pathway complement activity and proteinuria.
• Interim results from a Phase 1/2a clinical study of ARO-CFB demonstrated dose-dependent reductions in circulating CFB protein by up to 90% with greater than 3 months duration, and near complete inhibition of alternative pathway activity.
• Research and development expenses increased by $62.4 million, or 17%, for the nine months ended June 30, 2025, due to the progression of the pipeline.
• General and administrative expenses increased by $13.9 million, or 19%, for the nine months ended June 30, 2025, driven by commercialization and business development efforts.

Sentiment

Score: 8

Explanation: The company reported a substantial turnaround in its financial performance for the nine-month period, driven by a major collaboration agreement with Sarepta. Significant clinical and regulatory milestones were achieved for key pipeline assets, and a new strategic deal with Sanofi further strengthens the financial position and pipeline. While R&D expenses are high, they reflect active pipeline progression.

Positives

• Achieved a significant financial turnaround with net income of $22.1 million for the nine-month period, compared to a substantial loss in the prior year.
• Reported a massive increase in revenue to $573.0 million for the nine months, primarily from the Sarepta Collaboration Agreement.
• Maintained a strong liquidity position with $129.8 million in cash and $770.6 million in available-for-sale securities.
• Triggered a $100.0 million milestone payment from Sarepta for ARO-DM1, with potential for an additional $200.0 million in near-term milestones.
• Secured a strategic asset purchase agreement with Sanofi for plozasiran rights in Greater China, including a $130.0 million upfront payment and significant future milestones.
• Plozasiran's NDA for familial chylomicronemia syndrome (FCS) was accepted by the FDA with a PDUFA date of November 18, 2025, and no advisory committee planned, indicating a potentially smoother regulatory path.
• Successfully completed enrollment for three Phase 3 clinical trials of plozasiran for severe hypertriglyceridemia.
• Initiated a Phase 3 clinical trial for zodasiran, advancing a key cardiometabolic candidate.
• Reported positive clinical data for ARO-C3 and ARO-CFB, validating the RNAi platform's efficacy in complement-mediated diseases.
• Repaid $201.6 million of the credit facility during fiscal 2025, reducing long-term debt obligations.

Negatives

• Reported a net loss of $175.2 million for the three months ended June 30, 2025, a slight increase from the prior year's quarterly loss.
• Increased research and development expenses and general and administrative expenses reflect the high costs associated with advancing a broad pipeline and preparing for commercialization.
• Incurred significant non-cash interest expense related to the liability from the sale of future royalties and the credit facility.
• Net loss attributable to noncontrolling interest was $8.1 million for the nine months ended June 30, 2025.

Risks

• Forward-looking statements are subject to inherent risks and uncertainties, and actual results may differ materially from current expectations.
• Research and development activities require significant ongoing capital investment, particularly as drug candidates progress to later-stage clinical trials and commercialization.
• The company is subject to restrictions on sales and licensing transactions with respect to certain core intellectual property under the Financing Agreement.
• The company maintains a full valuation allowance, indicating that it does not anticipate a material change to its effective income tax rate or net deferred federal income tax assets.
• Estimates of future net product sales and resulting royalty payments are based on key assumptions (population, penetration, probability of success, sales price) which, if inaccurate, could affect the amortization of royalty financing obligations and the effective interest rate.

Future Outlook

Expects to have sufficient liquidity to fund operations through at least the next twelve months. The company is eligible to receive up to $13.3 billion in additional developmental, regulatory, and sales milestones, and various royalties from its licensing and collaboration agreements. The NDA for plozasiran (FCS) has a PDUFA action date of November 18, 2025, with no advisory committee meeting currently planned, suggesting a potential regulatory approval. The company anticipates continued significant cash expenditure for research and development as its pipeline expands and matures into later-stage clinical trials and commercialization.

Management Comments

• We intend that such forward-looking statements be subject to the safe harbors created thereby.
• TRiM™ enabled therapeutics offer several potential advantages over prior generations and competing technologies, including: simplified manufacturing and reduced costs; multiple routes of administration including subcutaneous injection and inhaled administration; the ability to target multiple tissue types including liver, lung, central nervous system (CNS), muscle, and adipose tissue; and the potential for improved safety and reduced risk of intracellular buildup, because there are fewer metabolites from smaller, simpler molecules.
• Based upon our current cash and investment resources and operating plan, we expect to have sufficient liquidity to fund our operations through at least the next twelve months from the date of the issuance of these unaudited consolidated financial statements.

Industry Context

NA

Management Changes

Legal Proceedings

• No material developments in legal proceedings from those disclosed in the Annual Report on Form 10-K for the fiscal year ended September 30, 2024.
• The company has been notified of an income tax examination by the State of California.

Stakeholder Impact

• Shareholders: Positive impact due to significant revenue growth, shift to profitability, strong cash position, and multiple clinical and regulatory advancements that de-risk the pipeline and offer future revenue potential. The Sarepta equity investment and pre-funded warrants also indicate investor confidence.
• Employees: Continued growth and expansion of the pipeline and facilities suggest job stability and potential for new opportunities. Stock-based compensation is a significant part of employee remuneration.
• Customers/Patients: Progress in clinical trials for various intractable diseases (e.g., hypertriglyceridemia, HoFH, DM1, obesity) offers hope for new therapeutic options.
• Partners (Sarepta, Sanofi, GSK, Takeda, Amgen): Strengthened relationships and continued collaboration, with milestone payments and co-development activities progressing.
• Creditors (Sixth Street Lending Partners, Bank of Zhejiang): Reduced credit facility balance and strong liquidity position improve creditworthiness.

Next Steps

• Regulatory approval of plozasiran (FCS) by the FDA, with a PDUFA action date of November 18, 2025.
• Continued development and commercialization of plozasiran in Greater China by Sanofi.
• Potential to receive an additional $200.0 million in near-term milestone payments from Sarepta for ARO-DM1.
• Ongoing clinical development of zodasiran (Phase 3), ARO-ALK7 (Phase 1/2a), ARO-INHBE (Phase 1/2a), ARO-C3 (Phase 1/2), and ARO-CFB (Phase 1/2a).
• Further development and sales milestones from existing collaboration agreements with GSK, Takeda, Amgen, and Sarepta.
• Evaluation of the impact of the One Big Beautiful Bill Act (OBBBA) on financial condition and results of operations.

Key Dates

Recommendation

The company has demonstrated exceptional progress across multiple fronts. The substantial revenue increase and shift to profitability for the nine-month period, driven by the Sarepta collaboration, significantly de-risks the financial profile. Key pipeline assets like plozasiran are nearing potential FDA approval with a clear PDUFA date and no advisory committee, which is a strong positive signal. The new Sanofi deal for plozasiran in Greater China adds another significant revenue stream. Continued advancement of other clinical programs and positive interim data further validate the RNAi platform. The strong liquidity position provides ample runway for future development and commercialization efforts. These factors collectively point to a highly favorable outlook and strong investment potential.

Keywords

RNAi therapeutics, Plozasiran, Zodasiran, ARO-DM1, Sarepta, Sanofi, FDA approval, Clinical trials, Cardiometabolic diseases, Rare genetic diseases, Drug development, Biotechnology, Pharmaceuticals, Milestone payments, Collaborations